These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 6608470)

  • 21. Circulating B and T lymphocytes in myeloma and benign monoclonal gammopathies.
    Büchi G; Termine G; Girotto M; Gario S; Autino R
    Haematologica; 1983; 68(2):179-89. PubMed ID: 6407913
    [No Abstract]   [Full Text] [Related]  

  • 22. Editorial: Cellular regulation of humoral immunity.
    Solomon A
    N Engl J Med; 1975 Oct; 293(18):928-9. PubMed ID: 1080835
    [No Abstract]   [Full Text] [Related]  

  • 23. Peripheral blood and bone marrow involvement by non-Hodgkin's lymphoma: morphological, immunological and cytochemical features.
    Cousar JB; Glick AD; York JC; Miers M; Collins RD
    Prog Clin Pathol; 1984; 9():173-96. PubMed ID: 6364222
    [No Abstract]   [Full Text] [Related]  

  • 24. [Behavior of thymus-dependent and bursa-dependent lymphocytes (T and B) in some lymphoproliferative diseases].
    Barabino A; Di Benedetto G; Franceschini R; Indiveri F; Puppo F; Soldà AM
    Boll Soc Ital Biol Sper; 1975 Nov; 51(22):1612-6. PubMed ID: 1084753
    [No Abstract]   [Full Text] [Related]  

  • 25. [Multiple myeloma].
    Almazov VA; Afanasév BV; Podoltseva ZI
    Klin Med (Mosk); 1993; 71(2):5-10. PubMed ID: 8046926
    [No Abstract]   [Full Text] [Related]  

  • 26. Circulating Ki67 positive lymphocytes in multiple myeloma and benign monoclonal gammopathy.
    Miguel-Garcia A; Matutes E; Tarin F; Garcia-Talavera J; Miguel-Sosa A; Carbonell F; Catovsky D
    J Clin Pathol; 1995 Sep; 48(9):835-9. PubMed ID: 7490317
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [On the cell surface markers of lymphocytes in lymphoproliferative disorders (author's transl)].
    Tanaka E
    Rinsho Ketsueki; 1976 Jun; 17(6):600-17. PubMed ID: 823349
    [No Abstract]   [Full Text] [Related]  

  • 28. Idiotypic immunoglobulin structures on blood lymphocytes in human plasma cell myeloma.
    Holm G; Mellstedt H; Pettersson D; Biberfeld R
    Immunol Rev; 1977; 34():139-64. PubMed ID: 66782
    [No Abstract]   [Full Text] [Related]  

  • 29. Impaired synthesis of polyclonal (non-paraprotein) immunoglobulins by circulating lymphocytes from patients with multiple myeloma Role of suppressor cells.
    Broder S; Humphrey R; Durm M; Blackman M; Meade B; Goldman C; Strober W; Waldmann T
    N Engl J Med; 1975 Oct; 293(18):887-92. PubMed ID: 1080834
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Evaluation of the effect of paraproteinemic sera on the capacity of normal lymphocytes for rosette E formation].
    Soldà AM; Barabino A; Franceschini R; Mavilio R; Indiveri F
    Boll Soc Ital Biol Sper; 1977 Apr; 53(7):526-30. PubMed ID: 303111
    [No Abstract]   [Full Text] [Related]  

  • 31. [Characteristics of immunological status of patients with lymphoblastic leukemia in relation to therapy].
    Shardakov VI; Riabov NV; Riabova TI; Timkina EN; Kopaneva TG
    Gematol Transfuziol; 1985 Jul; 30(7):19-21. PubMed ID: 3876962
    [No Abstract]   [Full Text] [Related]  

  • 32. B and T cell markers of bone marrow and peripheral blood lymphoid cells in patients with paraproteinaemia.
    Husz S; Krizsa F; Dobozy A; Hunyadi J; Simon N
    Acta Haematol; 1977; 57(6):321-30. PubMed ID: 70148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple myeloma with high tumour mass. Treatment with high-dose methylprednisolone, cyclophosphamide and vindesine.
    van Dobbenburgh OA; Halie MR; Piersma H; Marrink J; Ockhuizen T; Nieweg HO
    Eur J Cancer Clin Oncol; 1984 Mar; 20(3):437-9. PubMed ID: 6538503
    [No Abstract]   [Full Text] [Related]  

  • 34. Rate of M-component changes and clinical course of 23 responsive myeloma patients.
    Riccardi A; Montecucco C; Merlini G; Cremonini N; Danova M; Ascari E
    Haematologica; 1984; 69(3):305-14. PubMed ID: 6432642
    [No Abstract]   [Full Text] [Related]  

  • 35. Multiple myeloma, a 'B' cell blood dyscrasia.
    Anido V; Marcus G
    W V Med J; 1977 Sep; 73(9):221-5. PubMed ID: 302530
    [No Abstract]   [Full Text] [Related]  

  • 36. Nonsecretory multiple myeloma.
    Rubio-Felix D; Giralt M; Giraldo MP; Martinez-Peñuela JM; Oyarzabal F; Sala F; Raichs A
    Cancer; 1987 May; 59(10):1847-52. PubMed ID: 3828953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PAS staining and immunoglobulin classes in myeloma.
    Grozdea J; de Boissezon JF; Guiraud M; Martin J
    Lancet; 1980 Nov; 2(8202):1036. PubMed ID: 6107670
    [No Abstract]   [Full Text] [Related]  

  • 38. Changes in lymphocyte surface immunoglobulins in myeloma and the effect of an RNA-containing plasma factor.
    Chen Y; Bhoopalam N; Yakulis V; Heller P
    Ann Intern Med; 1975 Nov; 83(5):625-31. PubMed ID: 812401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of interferon-alpha on immunoglobulin production by peripheral blood mononuclear cells in multiple myeloma.
    Säily M; Koistinen P; Laine S; Soppi E; Savolainen ER
    Eur J Haematol; 1996 Aug; 57(2):171-7. PubMed ID: 8856095
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma.
    Jelinek T; Paiva B; Hajek R
    Front Immunol; 2018; 9():2431. PubMed ID: 30505301
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.